- Home
- PPL vs RPRX Comparison
PPL vs RPRX Comparison
Compare PPL & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PPL | RPRX |
|---|---|---|
| Founded | 1920 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3B | 22.0B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PPL | RPRX |
|---|---|---|
| Price | $35.33 | $55.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $41.08 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 8.5M | 3.0M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.95% | 1.90% |
| EPS Growth | ★ 32.50 | N/A |
| EPS | ★ 1.59 | 0.67 |
| Revenue | ★ $9,042,000,000.00 | $2,378,193,000.00 |
| Revenue This Year | $7.23 | $38.63 |
| Revenue Next Year | $5.85 | $4.73 |
| P/E Ratio | ★ $22.22 | $81.43 |
| Revenue Growth | ★ 6.85 | 5.06 |
| 52 Week Low | $33.17 | $32.65 |
| 52 Week High | $40.11 | $54.74 |
Technical Indicators
Market Signals| Indicator | PPL | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 73.17 |
| Support Level | $34.96 | $35.35 |
| Resistance Level | $37.12 | N/A |
| Average True Range (ATR) | 0.58 | 1.02 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 30.38 | 99.36 |
Price Performance
Historical ComparisonAbout PPL PPL Corporation
PPL is a holding company of regulated utilities in Pennsylvania, Kentucky, and Rhode Island. The Pennsylvania regulated delivery and transmission segment distributes electricity to customers in central and eastern Pennsylvania. In Kentucky, LG&E and KU are involved in regulated electricity generation, transmission, and distribution. LG&E also provides regulated natural gas distribution. Rhode Island Energy operates electric and gas utilities in the state.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.